Helius Medical Tech (NASDAQ:HSDT) Stock, Quote.Headers.trade-ideas

Helius Medical Tech

Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS), is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.

Movers

News

Intraday Update

Markets

ADTN

AGRI

AIRE

AMBC

AORT

ATSG

AUDC

BAND

BLDR

BTBD

BYON

CMND

COKE

CROX

DAVE

DDOG

EVER

FGEN

FWRG

GLDD

GSUN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HSDT

JELD

JJSF

JMIA

LCID

MSGM

NUVO

NUWE

PLTN

PLTR

PRGO

REAX

SELF

SGRY

STIM

STRL

TALK

TWKS

ZETA

Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

movers image

Pre-Market Outlook

Trading Ideas

TCBP

TRUP

TTOO

Why Zeta Global Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket

Government

Health Care

General

Helius Medical partners with Lovell Govt Services to provide PoNS device to federal healthcare systems. PoNS, a short-term treatment for gait deficit in MS, shows promising real-world results. Seeking FDA authorization for stroke treatment. HSDT shares surge 38% in premarket trading.

Why Is Nano-Cap Helius Medical Stock Trading Higher On Wednesday?

Helius Medical Technologies, Inc. - Class A Common Stock

Helius Medical Technologies Inc

Helius Medical Technologies Inc Warrants (02/02/2026)

In a recent fireside chat hosted by <a href="https://www.benzinga.com/topic/pablo-zuanic">Pablo Zuanic</a>, senior equity analyst, former U.S. Rep&nbsp;Ed Perlmutter shared his insights on the evolving cannabis landscape. 
With Congress grappling with cannabis rescheduling and banking reforms, Perlmutter&#39;s insider knowledge offers a crucial perspective for <a href="https://www.benzinga.com/cannabis">cannabis investors</a>.
&quot;When I first introduced this in 2013-2014, I had to deal with the chuckle factor,&quot; said&nbsp;Perlmutter, often hailed as the founding father&nbsp;of the SAFE Banking Bill.
The recent passage of a modified version, SAFER, in the Senate Banking Committee marks progress, yet the path forward remains uncertain. &quot;We&#39;re in campaign season now,&quot; Perlmutter warned, underscoring the time constraints.
<h3>Rescheduling And Political Landscape</h3>
During the chat, Perlmutter delved into the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39912859/as-election-buzz-swirls-around-biden-and-harris-dea-comment-period-ends-whats-next-">intricate process of cannabis rescheduling</a> initiated by President Joe Biden. The administrative procedure, bound by the Administrative Procedures Act, involves specific steps and timelines for public comment and hearings.
Perlmutter expressed optimism about Vice President Kamala Harris potentially taking the helm. Her prior sponsorship of the SAFE Banking Bill signals a strong understanding and support for cannabis reforms.
However, the upcoming elections introduce uncertainty. Perlmutter outlined a scenario where the current administration&#39;s initiatives might face challenges depending on the election outcomes.
He also highlighted the role of key players in Congress, such as Senate Majority Leader Chuck Schumer&nbsp;whose&nbsp;efforts to integrate cannabis reforms into broader legislative packages, such as the National Defense Authorization Act (NDAA) or a financial services bill&nbsp;could be pivotal. &quot;If he just brought it to the floor, it would pass,&quot; Perlmutter said, reflecting on the strategic legislative maneuvers necessary to secure passage.
Perlmutter discussed the potential impact of a GOP victory, suggesting it could stall or reverse progress on cannabis reforms. He noted that if Republicans take the White House, there could be a shift in priorities away from cannabis legislation.
Also read:&nbsp;<a href="https://www.benzinga.com/markets/cannabis/24/07/39946113/gop-attor-ney-gen-er-al-in-texas-loses-legal-battle-against-towns-with-decriminalized-cannabis-i">GOP Attor&shy;ney Gen&shy;er&shy;al In Texas Loses Legal Battle Against Towns With Decriminalized Cannabis, Insists They&#39;re &#39;Run By Pro-Crime Extremists&#39;</a>
<h3>The Road Ahead</h3>
Perlmutter remains optimistic about cannabis banking reform, possibly
through a larger financial services bill incorporating cryptocurrency regulations. &quot;There is a lot of discussion...where [banking reform]&nbsp;would be added to a financial services piece of legislation,&quot; he said.
Although cannabis rescheduling is in motion under the Administrative Procedures Act, the primary focus for Democrats would be winning the elections. He indicated that VP&nbsp;Harris and her potential running mate would prioritize election efforts, pointing out&nbsp;that<a href="https://www.benzinga.com/markets/cannabis/24/07/39920347/dallas-cannabis-reform-ballot-is-a-go-decriminalization-in-november-elections-would-allow-up-to-"> cannabis policy</a> is a crucial issue for many voters, enhancing its role in any forthcoming campaign strategy.
The methodical approach taken by the Biden administration ponders the question of whether rescheduling can happen in time or not. Perlmutter acknowledged the complexity of the situation.&nbsp;&quot;From the White House&#39;s point of view and the HHS, they&#39;ve done what they could do.&quot; He explained that the next phases are dictated by the Administrative Procedures Act, which requires specific timeframes for comments and hearings.
<h3>What If?</h3>
Perlmutter suggested a nuanced approach to cannabis policy even under <a href="https://www.benzinga.com/markets/cannabis/24/07/39964922/ron-desantis-says-florida-supreme-court-should-not-have-allowed-cannabis-legalization-initiative">conservative leadership</a>. Discussing the hypothetical scenario of a Trump presidency, Perlmutter pointed out that despite Jeff Sessions rescinding the Cole Memo, the FinCEN guidance remained intact. &quot;The president could have said to Secretary Mnuchin, let&#39;s get rid of the FinCEN guidance. And he didn&#39;t.&quot;&nbsp;
Regarding the future, Perlmutter expressed cautious optimism.&nbsp;&quot;The clock is ticking, no question about it. But at least it&#39;s ticking.&quot; He highlighted that despite the lengthy process, the momentum towards rescheduling is significant and unprecedented in over five decades.
Find the complete conversation <a href="https://www.youtube.com/@ZuanicAssociates">here</a>.&nbsp;
Read next:&nbsp;<a href="https://www.benzinga.com/markets/cannabis/24/07/39908764/harris-vs-trump-will-cannabis-rescheduling-survive-bidens-exit-analyst-on-potential-gop-victory">Harris Vs. Trump: Will Cannabis Rescheduling Survive Biden&#39;s Exit? Analyst On Potential GOP Victory</a>
These issues will be among the hot topics at the upcoming Benzinga Cannabis Capital Conference in Chicago this Oct. 8-9. Join us to get more insight into what the wave of weed legalization means for the future of investing in the&nbsp;industry. Hear directly from top executives, investors, advocates, and policymakers.&nbsp;<a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" rel="noreferrer noopener" target="_blank">Get your tickets now</a>&nbsp;before prices go up by following&nbsp;<a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" rel="noreferrer noopener" target="_blank">this link</a>.
Photo: AI-generated image.&nbsp;

Analyst Color

Cannabis

Regulations

Politics

Legal

Exclusives

Analyst Ratings

Interview

'The Clock Is Ticking' For Cannabis Rescheduling, Says Former Congressman Ed Perlmutter

Vice President Kamala Harris is making headlines as she prepares to become the Democratic nominee for president in the <a href="https://www.benzinga.com/topic/2024-election">2024 election</a> after President Joe Biden <a href="https://www.benzinga.com/markets/cannabis/24/07/39874209/joe-biden-drops-out-what-would-happen-with-cannabis-legalization-under-kamala-harris-or-donald-t">opted not to seek reelection.</a>
If Harris secures the Democratic nomination and wins the presidency, she would make history as the first major party presidential nominee to fully support marijuana legalization.
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/07/39912303/kamala-harris-prospective-vp-picks-all-seem-to-support-cannabis-legalization-5-names-in-the-mix">Kamala Harris&#8217; Prospective VP Picks All Seem To Support Cannabis Legalization: 6 Names In The Mix</a>
Harris even admitted to having smoked marijuana in college. In a 2019 interview on the popular morning radio show, The Breakfast Club, Harris candidly discussed her personal experience with cannabis.
When asked by host Charlamagne tha God if she had ever smoked marijuana, Harris responded with a laugh: &#8220;I have. And I inhaled. I did inhale,&#8221; she said, taking a lighthearted jab at former President Bill Clinton's claim that he smoked but didn't inhale. 
&#8220;It was a long time ago but yes,&#8221; she added. &#8220;I just broke news.&#8221;
In that prominent interview, Harris also disputed reports that she doesn&#8217;t support legalizing marijuana: &#8220;That&#8217;s not true. I think that it gives a lot of people joy and we need more joy.&#8221;
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="A play-by-play of Kamala Harris admitting she smoked weed" width="500" height="281" src="https://www.youtube.com/embed/kKMwua-_jlQ?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
<h3 class="wp-block-heading">A Strong Supporter Of Marijuana Legalization</h3>
Harris has consistently advocated for cannabis legalization throughout her political career, with her stance <a href="https://www.benzinga.com/markets/cannabis/24/07/39890659/kamala-harris-u-turn-on-cannabis-heres-where-she-stands-on-weed-legalization-now">evolving significantly over time.</a> Initially, as the District Attorney of San Francisco, she opposed California&#8217;s Proposition 19 in 2010, which sought to legalize marijuana.
However, her position began to shift during her tenure as a U.S. Senator and Vice President.
Key moments of her advocacy include:
<ul>
<li>2015: Harris called for an end to the federal ban on medical marijuana during the Democratic State Convention.</li>
<li>2018: She co-sponsored the Marijuana Justice Act, aimed at legalizing marijuana at the federal level and addressing racial disparities in cannabis-related arrests.</li>
<li>2019: During an interview, she publicly supported cannabis legalization and shared her own experiences with marijuana.</li>
<li>2020: Harris's presidential campaign emphasized her commitment to cannabis reform, including the expungement of nonviolent marijuana-related offenses.</li>
<li>2024: As recently as March, she reiterated her call for legalization during discussions with marijuana pardon recipients, framing it as a critical issue of criminal justice reform.</li>
</ul>
In addition to her public support for the Marijuana Justice Act, Harris has advocated for broader marijuana reform in her book, &#8220;The Truths We Hold: An American Journey.&#8221; She has called for the legalization of marijuana and the expungement of past marijuana-related offenses from individuals' records.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/06/39212969/kamala-harris-gets-her-own-cannabis-strain-kamala-kush-whether-she-likes-it-or-not-watch-jimmy-k">Kamala Harris Gets Her Own Cannabis Strain &#8216;Kamala Kush&#8217; Whether She Likes It Or Not: Watch Jimmy Kimmel Break The News To Her</a></li>
</ul>

Kamala Harris Admits 'I Inhaled' Marijuana And Now Pushes For Legalization: What This Means For 2024 Elections

IAC chairman Barry Diller&nbsp;on Friday praised Vice President Kamala Harris while recounting what happened after President Joe Biden last week <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39885549/biden-withdraws-from-2024-race-what-that-means-for-solana-etf-prospects">decided to exit</a> the 2024 presidential race.
What Happened: While appearing on CNBC, Diller said he was impressed by Harris&#8217;s quick mobilization of her team following Biden&#8217;s decision not to run for re-election.
&#8220;Within&nbsp;a millisecond of Biden telling&nbsp;her I&#8217;m not going, she&nbsp;mobilized her forces and within&nbsp;12 hours, she shut everyone&nbsp;else down,&#8221; he said.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39948413/trump-era-white-house-official-anthony-scaramucci-says-kamala-harris-is-capable-and-has-a-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump-Era White House Official Anthony Scaramucci Says Kamala Harris Is Capable And Has A Great Team: &#8216;Look Forward To Seeing Her Policies On Crypto&#8217;</a>
The media mogul said he initially hoped for an open convention, where multiple candidates, including Harris, would compete, creating a vibrant democratic process. 
However, he recognized Harris&#8217;s confidence and organizational skills in securing endorsements and eliminating competition.
&#8220;It was her. She organized the endorsements leading with the Clintons and everybody else,&#8221; Diller added.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&quot;Do not discount Kamala Harris,&quot; says IAC Chairman Barry Diller. &quot;Because within a millisecond of Biden telling her I&#39;m not going, she mobilized her forces and within 12 hours, she shut everyone else down.&quot; <a href="https://t.co/Hsb02gwTHR">pic.twitter.com/Hsb02gwTHR</a>
&mdash; Squawk Box (@SquawkCNBC) <a href="https://twitter.com/SquawkCNBC/status/1816835497706070510?ref_src=twsrc%5Etfw">July 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: A <a href="https://www.benzinga.com/news/24/07/39996908/trump-vs-harris-new-poll-shows-ex-president-leading-democratic-candidate-by-a-narrow-margin-but-vice">poll conducted by The Wall Street Journal</a>, results of which were made public on Friday, showed former President Donald Trump leading Harris by a narrow margin. Moreover, Harris&#8217;s favorability among registered voters was on the rise.
Another report from the same day highlighted <a href="https://www.benzinga.com/general/politics/24/07/39973800/trump-vs-harris-vice-president-gains-ground-lost-by-joe-biden-in-swing-states">Harris&#8217;s growing support in swing states</a> compared to where the President stood earlier this month.
Meanwhile, there&#8217;s also speculation about whether <a href="https://www.benzinga.com/news/24/07/39979544/can-trump-replace-jd-vance-amid-kamala-harris-picking-pace-experts-warn-that-could-be-extraordinaril">Trump might replace his</a> vice presidential candidate, Sen. J.D. Vance (R-Ohio), due to his underwhelming polling. This is in the wake of Harris gaining momentum.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/07/39964922/ron-desantis-says-florida-supreme-court-should-not-have-allowed-cannabis-legalization-initiative?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Ron DeSantis Says Florida Supreme Court Should &#8216;Not Have Allowed&#8217; Cannabis Legalization Initiative On Ballot</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Media

'Don't Discount Kamala Harris Yet,' Says IAC Chairman Barry Diller, Recounting How 'She Mobilized Her Forces And… Shut Everyone Else Down' Within Hours Of Biden Stepping Down

Former White House Communications Director Anthony Scaramucci weighed in on the possible impact on Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) prices if former President Donald Trump wins his second term in the upcoming elections, <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39994378/bitcoin-ethereum-dogecoin-zoom-higher-as-bitcoin-conference-awaits-donald-trumps-keynote-s">ahead of the Bitcoin 2024 conference</a>.
What Happened: Scaramucci, a known proponent of Bitcoin and cryptocurrencies as an asset class, highlighted how a second Trump presidency could influence prices of the apex crypto, in an interview with CNBC.
"I applaud President Trump for that."
He also went into detail about the stance of the Democratic party and how Trump&#8217;s outreach to cryptocurrency proponents has taken his rivals by surprise.
"I think President Trump's move to court Bitcoin and towards crypto assets has shaken the Democrats at core."
See Also: <a href="https://www.benzinga.com/news/24/07/39997008/janet-yellen-rejects-economist-roubinis-and-trump-era-officials-claims-of-manipulation-in-treasuries">Janet Yellen Rejects Economist Roubini&#8217;s And Trump-Era Official&#8217;s Claims Of &#8216;Manipulation&#8217; In Treasuries</a>
Scaramucci, who started investing in Bitcoin in 2020 and is <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39960622/anthony-scaramucci-writing-bitcoin-book-with-michael-saylor-this-is-where-the-future-is">writing a book</a> on King Crypto, also had a word of caution for Democrats.
"Very smart, younger Democrats are recognizing that they're way off base with their positions, they're way off with these SEC lawsuits and regulation by enforcement," he added.
The former White House official also underscored his belief that Trump would be "very well welcomed" at the Bitcoin 2024 conference, where the former president is scheduled to deliver the keynote address.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Fmr. President Trump is set to deliver a keynote address at the Bitcoin Conference in Nashville. Here&#39;s Anthony Scaramucci on what a second Trump Presidency could mean for bitcoin prices. <a href="https://t.co/L62svncI0Q">pic.twitter.com/L62svncI0Q</a>
&mdash; Squawk Box (@SquawkCNBC) <a href="https://twitter.com/SquawkCNBC/status/1816815455958606023?ref_src=twsrc%5Etfw">July 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Ahead of the conference, Sen. Tim Scott (R-S.C) underscored the importance of the King Crypto, saying, "Bitcoin's future has to be in America. What we know about the Biden administration and the SEC, is that they are anti-Bitcoin, anti-digital assets."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Former President Trump is scheduled to address <a href="https://twitter.com/hashtag/Bitcoin2024?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin2024</a> this weekend, having warmed to cryptocurrency after previously calling it a &quot;scam.&quot;<a href="https://twitter.com/SenatorTimScott?ref_src=twsrc%5Etfw">@SenatorTimScott</a> weighs in. <a href="https://t.co/BzyNvlLEgK">pic.twitter.com/BzyNvlLEgK</a>
&mdash; Squawk Box (@SquawkCNBC) <a href="https://twitter.com/SquawkCNBC/status/1816857653840146584?ref_src=twsrc%5Etfw">July 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: The optimism among Bitcoin supporters has been rising in light of the possibility of Trump winning his second term, with Bitcoin conference fundraiser tickets <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39856556/trumps-bitcoin-conference-fundraiser-tickets-skyrocket-to-844k">skyrocketing to $844,600 per person</a>.
Analysts at research and brokerage firm Bernstein think that a Trump win <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39897980/potential-trump-victory-could-stir-bitcoin-market-bernstein-analysts-predict-implications-">could also stir the Bitcoin market</a>. They believe that the market has not yet accounted for a positive shift in cryptocurrency regulations if Trump is re-elected in November.
There are rumors that Trump might also announce <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39866338/bitcoin-as-a-strategic-reserve-asset-for-the-us-expert-details-how-trump-could-make-it-hap">Bitcoin as a strategic reserve asset</a> during the Bitcoin conference on July 27.
Price Action: At the time of writing, Bitcoin was trading at $67,965, up 1.43% in the last 24 hours, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Bitcoin has surged nearly 54% in 2024 so far.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39997182/former-white-house-official-anthony-scaramucci-mocks-jd-vance-says-thank-you-for-knocking-me-out-of">Former White House Official Anthony Scaramucci Mocks JD Vance, Says Thank You For &#8216;Knocking Me Out Of The Position Of The Worst Donald Trump Hire&#8217;</a></li>
</ul>
Image generated using Midjourney

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Anthony Scaramucci, Tim Scott Weigh In Ahead Of Ex-President's Address At Bitcoin 2024 Conference: 'Trump's Move To Court Bitcoin And Towards Crypto Assets Has Shaken The Democrats At Core'

French billionaire Bernard Arnault recalled the time when he and Elon Musk, the CEO of Tesla and SpaceX, discussed the idea of a Louis Vuitton-branded rocket.
What Happened: While appearing on CNBC&#8217;s Squawk Box, Arnault spoke about his discussions with Musk. &#8220;I admire very much what he's doing because I think he's a genius. To do such a success with a car company was quite unexpected. But he's a genius,&#8221; he said.
The French luxury mogul went on to reveal that the last time the two billionaires talked about an idea involving a rocket. &#8220;Maybe we have a way to put Vuitton in a rocket. I don't know if we go somewhere.&#8221;
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/07/39926076/mark-zuckerberg-slams-tim-cooks-apple-after-cupertino-reportedly-rejected-its-iphone-ai-partnership?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Mark Zuckerberg Slams Tim Cook&#8217;s Apple After Cupertino Reportedly Rejected Its iPhone AI Partnership Proposal: &#8216;They Wanted To Put Us In A Box…&#8217;</a>
When questioned about the possibility of branding the rocket&#8217;s exterior with Louis Vuitton, Arnault responded, &#8220;Maybe the inside. I don't&nbsp;know. We have to —&nbsp;we have to think. He&nbsp;did not say no.&#8221;
Arnault then humorously voiced his apprehension, saying, &#8220;I'm afraid he will ask me to go with him in the rocket.&#8221; When asked if he would go on the rocket, Arnault said &#8220;I'm not sure.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">"Last time we discussed one idea, which is a rocket. Maybe we have a way to put Louis Vuitton in a rocket. I don&#39;t know if we go somewhere," says <a href="https://twitter.com/LVMH?ref_src=twsrc%5Etfw">@LVMH</a> CEO Bernard Arnault on his last conversation with <a href="https://twitter.com/elonmusk?ref_src=twsrc%5Etfw">@ElonMusk</a>. "I&#39;m afraid he will ask me to go with him in the rocket." <a href="https://t.co/lg5VbihOsk">pic.twitter.com/lg5VbihOsk</a>
&mdash; Squawk Box (@SquawkCNBC) <a href="https://twitter.com/SquawkCNBC/status/1816800297840251253?ref_src=twsrc%5Etfw">July 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: Last year in June, it was reported that <a href="https://www.benzinga.com/news/23/06/32905288/elon-musk-and-bernard-arnault-meet-for-power-lunch-in-paris-what-the-worlds-two-richest-men-discusse">Musk and Arnault had lunch</a> together in Paris. They reportedly met at one of Europe&#8217;s most luxurious hotels, the Cheval Blanc, where opulent rooms offer a breathtaking view of the Eiffel Tower.
Musk is currently the wealthiest person in the world with a net worth of $243 billion. Meanwhile, Arnault has a net worth of $188 billion, making him the third richest person on Bloomberg&#8217;s Billionaire <a href="https://www.bloomberg.com/billionaires/">Index</a>.
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39947719/elon-musk-says-he-will-fight-mark-zuckerberg-any-place-any-time-any-rules-cage-match-vibes-anyone?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Says He Will Fight Mark Zuckerberg &#8216;Any Place, Any Time, Any Rules&#8217; — &#8216;Cage Match&#8217; Vibes Anyone?</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photos courtesy: Shutterstock

SPACE

Tech

Elon Musk, Bernard Arnault Once Discussed Potential SpaceX-Louis Vuitton Collab: 'I'm Afraid He Will Ask Me To Go With Him In The Rocket'

French luxury mogul Bernard Arnault on Friday disclosed that the late Steve Jobs had once sought his counsel on the retail strategy for Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), despite skepticism from industry rivals.
What Happened: While appearing on CNBC, Arnault reminisced about a conversation with Jobs when Apple was considering the launch of its first retail store. The late Apple co-founder intrigued by Arnault&#8217;s success with the luxury brand Vuitton, sought his views on the venture.
Arnault said that he suggested Jobs inaugurate the first Apple store at a prime location, hinting at emulating Vuitton&#8217;s strategy. The first Apple store was launched in Tokyo, directly across a Vuitton outlet on Ginza, and it turned out to be a massive success.
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/07/39902838/broadcom-to-challenge-nvidia-dominance-analyst-says-jensen-huang-led-chip-giants-competitor-is-catch?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Broadcom To Challenge Nvidia Dominance? Analyst Says Jensen Huang-Led Chip Giant&#8217;s Competitor Is &#8216;Catchin</a>
Arnault said that Michael Dell, the founder of Dell Technologies, had expressed reservations about Apple&#8217;s direct retail strategy. &#8220;It proved to be a fantastic success. When, at the time, many of his competitors, I remember Dell, for instance, saying it would never work, these direct shops,&#8221; he stated.
During their interaction, Jobs also acknowledged the durability of Arnault&#8217;s products, contrasting it with the unpredictability of the tech industry&#8217;s success over time.
&#8220;He was very smart, obviously, and very creative also. But he told me, &#8216;You know, I like your products. And you have an advantage on me.&#8217; I said, &#8216;Well, which one?&#8217; &#8216;I don't know if my iPod will still be successful in 10 years. But what I know is your Dom Perignon will be sold in a century,'&#8221; Arnault said.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">.<a href="https://twitter.com/LVMH?ref_src=twsrc%5Etfw">@LVMH</a> Chairman and CEO Bernard Arnault on speaking with Steve Jobs when Apple was thinking about opening its first retail store: "It proved to be a fantastic success. When at the time many of his competitors, I remember [Michael] Dell for instance, saying it would never work." <a href="https://t.co/Ex3ypFMmzq">pic.twitter.com/Ex3ypFMmzq</a>
&mdash; Squawk Box (@SquawkCNBC) <a href="https://twitter.com/SquawkCNBC/status/1816819168617824402?ref_src=twsrc%5Etfw">July 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: Bernard Arnault&#8217;s advice to Steve Jobs came from his extensive experience in the luxury retail sector. His success with Vuitton is a testament to his understanding of the retail landscape.
The French luxury mogul currently has a net worth of $188 billion, making him the third wealthiest individual in the world, according to the Bloomberg Billionaire <a href="https://www.bloomberg.com/billionaires/">Index</a>. However, Arnault&#8217;s fortune has seen a <a href="https://www.benzinga.com/news/large-cap/24/07/39920045/arnaults-fortune-falls-as-lvmh-misses-on-earnings-zuckerberg-now-eyes-third-spot-on-billionaires-l">significant drop recently</a>. 
Earlier this week, it was reported that nearly half of Arnault's wealth is tied to his stake in LVMH-Moët Hennessy Louis Vuitton, which saw a nearly 5% decline in over-the-counter shares after earnings fell short of expectations.
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39947719/elon-musk-says-he-will-fight-mark-zuckerberg-any-place-any-time-any-rules-cage-match-vibes-anyone?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Says He Will Fight Mark Zuckerberg &#8216;Any Place, Any Time, Any Rules&#8217; — &#8216;Cage Match&#8217; Vibes Anyone?</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Shutterstock

AAPL

Steve Jobs Once Consulted Bernard Arnault When Apple Was Opening Its First Retail Store: French Luxury Tycoon Says 'It Proved To Be A Fantastic Success. When At The Time Many Of His Competitors…Saying It Would Never Work.'

Robert F. Kennedy Jr., an independent U.S. presidential candidate, raised questions about the recent pro-cryptocurrency stance of GOP nominee Donald Trump. This comes as both candidates vie for the support of crypto-holders at the Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39470346/trump-reportedly-discussing-participation-in-bitcoin-2024-conference-move-to-reinforce-cry">2024 conference.</a>
What Happened: Kennedy, who is currently favored by 8% of voters, expressed skepticism about Trump&#8217;s newfound support for cryptocurrency. He made these remarks at the Bitcoin 2024 conference in Nashville, Tennessee, where Trump is scheduled to speak on Saturday, Reuters reported.
In his conference speech, Kennedy took a jab at Trump, saying, &#8220;President Trump has orange hair&#8230; But I have an orange heart,&#8221; referring to the color of the Bitcoin logo. He expressed hope that Trump&#8217;s commitment to bitcoin is more than just political convenience.
&#8220;I hope President Trump&#8217;s commitment to Bitcoin is more than political expediency.&#8221;
Despite his low polling numbers, Kennedy&#8217;s candidacy could have a significant impact on the election if he draws voters away from Trump or the likely Democratic nominee, Kamala Harris. However, Kennedy has yet to qualify for the ballot in many states.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39963958/polymarket-trader-has-bet-over-1m-on-president-biden-to-not-finish-his-term-heres-how-that">Polymarket Trader Has Bet Over $1M On President Biden To Not Finish His Term: Here&#8217;s How That Is Going</a>
Kennedy also pledged that, if elected, he would instruct the U.S. Treasury to acquire enough Bitcoin to build a reserve similar to U.S. gold reserves, and would make direct ownership of Bitcoin tax-free.
Conference attendees are eagerly anticipating Trump&#8217;s speech on Saturday. &#8220;Make Bitcoin Great Again&#8221; red hats, a play on Trump&#8217;s &#8220;Make America Great Again&#8221; slogan, are being sold at the conference.
Why It Matters: Trump&#8217;s recent endorsement of cryptocurrency, despite previously calling it a &#8220;scam&#8221; in 2021, has been seen as a strategic move to gain support from the crypto community. The Republican Party has been actively courting crypto holders by promising lighter regulations.
Economist Peter Schiff has suggested that <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39975390/trumps-bitcoin-support-a-political-no-brainer-to-garner-votes-says-peter-schiff-promise-to">Trump&#8217;s support for Bitcoin</a> is a political move to gain votes, not a genuine commitment to make it a reserve asset. Schiff also warned that by pursuing cryptocurrency-supporting voters, Trump risks alienating supporters who do not trust the asset&#8217;s potential.
On the other hand, analysts from research and brokerage firm Bernstein have suggested that a potential Trump victory in the 2024 elections could significantly <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39897980/potential-trump-victory-could-stir-bitcoin-market-bernstein-analysts-predict-implications-">shake up the cryptocurrency market. </a>The Bernstein team posits that the market has not accounted for a potential positive shift in cryptocurrency regulations if Trump is reelected in November.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39900472/rich-dad-poor-dad-author-robert-kiyosaki-predicts-bitcoin-gold-and-silver-prices-will-soar">&#8216;Rich Dad Poor Dad&#8217; Author Robert Kiyosaki Predicts Bitcoin, Gold, And Silver Prices Will Soar If Trump Wins 2024 Election</a></li>
</ul>
Photo via Shutterstock

Robert F. Kennedy Jr. Questions Trump's Pro-Crypto Stance As 2024 Presidential Race Heats Up: 'I Hope...Commitment To Bitcoin Is More Than Political Expediency'

A gathering meant to rally support for Vice President&nbsp;Kamala Harris&#8216; presidential campaign morphed into an <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39919247/who-will-kamala-harris-pick-for-vice-president-crypto-bettors-have-4-favorites-for-democra">endorsement event for</a> Pennsylvania Governor&nbsp;Josh Shapiro (D-Pa.).
What Happened: The event on Friday, which saw Democratic leaders and labor unions come together to express their support for Harris, unexpectedly shifted its focus to Shapiro. 
Several speakers, including influential union leaders,&nbsp;the chair of the Philadelphia&nbsp;Democratic Party,&nbsp;and Philadelphia Mayor Cherelle Parker, endorsed Shapiro as a potential vice presidential candidate, <a href="https://www.politico.com/news/2024/07/26/philly-unions-democrats-shapiro-00171491">reported</a>&nbsp;Politico.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/cannabis/24/07/39964922/ron-desantis-says-florida-supreme-court-should-not-have-allowed-cannabis-legalization-initiative?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Ron DeSantis Says Florida Supreme Court Should &#8216;Not Have Allowed&#8217; Cannabis Legalization Initiative On Ballot</a>
&#8220;If they take our advice, Josh Shapiro will be our vice president,&#8221; Parker stated, highlighting Shapiro&#8217;s capability to secure a win in Pennsylvania.
Despite the public endorsements, Shapiro has not openly expressed interest in the VP position, stating that the decision lies with Harris. 
However, his allies, including Ryan Boyer,&nbsp;the leader of Philadelphia's powerful&nbsp;building trades council, have been vocal about Shapiro&#8217;s suitability for the White House. &#8220;He would look good on 1600 Pennsylvania Avenue.&#8221;
Why It Matters: Shapiro, who is reportedly&nbsp;being vetted by the Covington&nbsp;&amp; Burling law firm for the VP role, has been actively increasing his public presence.
He is scheduled&nbsp;to lead a Harris volunteer&nbsp;kick-off in central Pennsylvania on Saturday and will return to Philadelphia&nbsp;on Monday for an event&nbsp;with Michigan Governor Gretchen Whitmer.
According to Democratic mega-donors, Shapiro, Sen. Mark Kelly (D-Ariz.), and Roy Cooper (D-N.C.) are leading the race to become <a href="https://www.benzinga.com/news/24/07/39924772/democratic-mega-donors-predict-kamala-harris-to-pick-vp-among-these-3-lawmakers-as-presidential-race">Harris's running mate</a>.
Harris is preparing for a potential face-off against former President Donald Trump in the 2024 election. The choice of a running mate could significantly influence the election outcome. 
There are also speculations that Trump could <a href="https://www.benzinga.com/news/24/07/39979544/can-trump-replace-jd-vance-amid-kamala-harris-picking-pace-experts-warn-that-could-be-extraordinaril">replace his current running mate</a>, Sen. J.D. Vance (R-Ohio), due to his underwhelming polling.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39922362/hillary-clinton-says-kamala-harris-is-chronically-underestimated-says-vp-can-prosecute-a-compelling?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Hillary Clinton Says Kamala Harris is &#8216;Chronically Underestimated&#8217; — Says VP Can &#8216;Prosecute A Compelling Case&#8217; Against Failed President Trump</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Via Shutterstock

Josh Shapiro Emerges As Potential VP Candidate At Kamala Harris Endorsement Event: 'He Would Look Good...'

Former White House Communications Director Anthony Scaramucci humorously thanked Donald Trump's <a href="https://www.benzinga.com/general/politics/24/07/39780777/trump-picks-senator-j-d-vance-as-running-mate-musk-says-great-choice-for-vp">running mate</a>, JD Vance (R-Ohio), for taking his place as the worst hire of the former president.
What Happened: Scaramucci expressed his gratitude to Vance for ousting him from the position of the worst Trump hire, in a post on Friday on social media platform X, formerly Twitter.
&#8220;I just want to personally thank JD Vance for knocking me out of the position of the worst Donald Trump hire. I didn't think it would happen but here we are and I am grateful.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I just want to personally thank <a href="https://twitter.com/JDVance?ref_src=twsrc%5Etfw">@JDVance</a> for knocking me out of the position of the worst Donald Trump hire. I didn't think it would happen but here we are and I am grateful. &#x1f64f;
&mdash; Anthony Scaramucci (@Scaramucci) <a href="https://twitter.com/Scaramucci/status/1816928720894169307?ref_src=twsrc%5Etfw">July 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/news/23/11/35952778/former-doj-attorney-calls-marjorie-taylor-greenes-new-book-score-settling-fiction-that-reads-like-an?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Ex-DOJ Attorney Calls Marjorie Taylor Greene&#8217;s New Book &#8216;Score-Settling Fiction&#8217;</a>
Scaramucci&#8217;s post comes amidst <a href="https://www.benzinga.com/news/24/07/39979544/can-trump-replace-jd-vance-amid-kamala-harris-picking-pace-experts-warn-that-could-be-extraordinaril">growing speculation</a> about Vance&#8217;s position as Trump&#8217;s Vice Presidential candidate due to his underwhelming polling and the rising momentum of Vice President Kamala Harris.
Why It Matters: Scaramucci has been vocal about his disapproval of Vance as Trump&#8217;s running mate. He <a href="https://www.benzinga.com/news/24/07/39854646/anthony-scaramucci-says-jd-vances-quest-to-wall-us-off-from-rest-of-world-could-be-an-economic-disas">previously stated</a> that Vance&#8217;s economic policies could lead to a disaster for the United States and the world.
He also <a href="https://www.benzinga.com/news/24/07/39787296/first-obvious-error-by-trump-after-winning-nomination-says-anthony-scaramucci-of-ex-president-picks">criticized</a> Trump&#8217;s decision to pick Vance as his running mate, calling it the &#8220;first obvious error&#8221; by Trump after winning the nomination.
Vance has also <a href="https://www.benzinga.com/news/24/07/39784888/aoc-mocks-trump-vp-choice-j-d-vance-for-tweet-connecting-fertility-rate-with-daylight-saving-time">come under criticism</a> for his past social media activity, with Rep.&nbsp;Alexandria Ocasio-Cortez&nbsp;(D-N.Y.) highlighting a post made by Trump's running mate linking fertility rates with daylight savings time.
Vance reportedly wrote on November 1, 2020: "As a parent of young children and a nationalist who worries about America's low fertility I can say with confidence that daylight savings time reduces fertility by at least 10 percent."
Vance later said this post was a joke.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/01/36877020/robert-f-kennedy-jr-doesnt-want-to-be-trumps-vice-president-pick-heres-why?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Robert F. Kennedy Jr. Doesn&#8217;t Want To Be Trump&#8217;s Vice President Pick, Here&#8217;s Why</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo by Al Teich on Shutterstock

Former White House Official Anthony Scaramucci Mocks JD Vance, Says Thank You For 'Knocking Me Out Of The Position Of The Worst Donald Trump Hire'

Deepwater Asset Management&#8217;s managing partners, Gene Munster and Doug Clinton have <a href="https://www.businessinsider.in/tech/news/openais-new-searchgpt-prototype-is-a-declaration-of-war-against-google/articleshow/112024630.cms">downplayed concerns</a> that Alphabet Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google Search could be outdone by OpenAI&#8217;s SearchGPT.
What Happened: On Friday, Munster took to X, formerly Twitter, and said, &#8220;Since it&#8217;s only a 15-second video, it&#8217;s hard to see why SearchGPT is 10x better than Google AI Overviews.&#8221;
He went on to say that in the near term, this revives fears among Google investors that AI could threaten search. However, if the product&#8217;s capabilities are limited to what&#8217;s shown in the teaser, Google is not in any significant danger.
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/07/39922283/elon-musk-is-polling-x-and-asking-if-tesla-should-invest-5b-in-grok-parent-xai-this-is-just-to-test?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Is Polling X And Asking If Tesla Should Invest $5B In Grok Parent xAI: &#8216;This Is Just To Test The Waters&#8217;</a>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Since its only a 15 second video, it&#39;s hard to see why SearchGPT is 10x better than Google AI Overviews. Near-term this revive fears from <a href="https://twitter.com/search?q=%24GOOG&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$GOOG</a> investors that AI can kill search. If this is the product, Google is not in any meaningful danger. <a href="https://t.co/YX4Qa4Smac">https://t.co/YX4Qa4Smac</a>
&mdash; Gene Munster (@munster_gene) <a href="https://twitter.com/munster_gene/status/1816549429782151403?ref_src=twsrc%5Etfw">July 25, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Doug Clinton, the other managing partner at Deepwater, concurred with Munster&#8217;s views. He said that although the SearchGPT video resulted in a minor dip in Google&#8217;s stock, it does not pose a substantial threat to Google&#8217;s AI.
&#8220;It didn&#8217;t seem 10x superior to what I&#8217;m observing&nbsp;from Google and AI overviews,&#8221; Clinton remarked in a separate video.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">On this week&#39;s DeepTech315, <a href="https://twitter.com/dougclinton?ref_src=twsrc%5Etfw">@dougclinton</a> and I discuss <a href="https://twitter.com/search?q=%24TSLA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$TSLA</a> and <a href="https://twitter.com/search?q=%24GOOG&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$GOOG</a> earnings, and OpenAI&#39;s new search product, SearchGPT. <a href="https://t.co/9cGt75OwAu">pic.twitter.com/9cGt75OwAu</a>
&mdash; Gene Munster (@munster_gene) <a href="https://twitter.com/munster_gene/status/1816565516309295351?ref_src=twsrc%5Etfw">July 25, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Both partners concurred that unless SearchGPT can offer something unique or more than what was shown in the teaser, it&#8217;s difficult to see why users would switch from Google.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: On Thursday, Alphabet shares were trading lower after a <a href="https://www.benzinga.com/news/24/07/39968522/alphabet-stock-falls-as-openai-plans-searchgpt-what-investors-need-to-know">report suggested that OpenAI plans</a> to launch an online search tool called &#8220;SearchGPT&#8221; to disrupt Google's Search dominance.
Soon after, ChatGPT-parent, announced that it is testing SearchGPT, a temporary prototype of new AI search features. The launch is initially limited to a small group of users for feedback, with plans to integrate the experience into ChatGPT, the company stated.
Price Action: At the time of writing, Alphabet's Class A shares were down by 0.072% in after-hours trading to $166.88, while Class C shares dropped 0.018% to $168.65. During the regular session, Class A and Class C shares had closed at $167 and $168.68, respectively, according to<a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener">&nbsp;Benzinga Pro data</a>.
Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39929189/elon-musk-agrees-with-mark-zuckerberg-on-apple-tesla-ceo-wonders-how-many-enemies-he-can-make-and-su?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Agrees With Mark Zuckerberg On Apple, Tesla CEO Wonders How Many Enemies He Can Make And Survive</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Google Photo by DenPhotos on Shutterstock

GOOG

GOOGL

Top Analyst Says OpenAI's AI-Powered Search Engine Likely Isn't A Threat To Google: 'It's Hard To See Why SearchGPT Is 10X Better…'

The much-anticipated initial public offering (IPO) of billionaire investor Bill Ackman&#8216;s Pershing Square closed-end fund has been postponed, as confirmed by the New York Stock Exchange (NYSE.)
What Happened: On Friday, the NYSE announced on its website that the listing of Pershing Square USA Ltd. has been delayed, with a new date yet to be disclosed. 
Pershing Square refrained from commenting further but issued a statement clarifying that the IPO is still proceeding, with the pricing date to be announced later.
See Also: <a href="https://www.benzinga.com/news/24/07/39947623/lindsey-graham-says-americans-are-struggling-and-our-country-is-heading-in-the-wrong-direction-repla?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Lindsey Graham Says &#8216;Americans Are Struggling, And Our Country Is Heading In The Wrong Direction&#8217;</a>
The delay comes amid Ackman&#8217;s concerns about the size of the transaction and the novelty of the structure. He expressed these concerns in a July 24 letter to investors, emphasizing the need for careful analysis and judgment from investors.
The fund is expected to invest in 12 to 24 large-cap, investment-grade, &#8220;durable growth&#8221; companies in North America. The public listing is seen as a move to leverage Ackman&#8217;s following among Main Street investors.
Why It Matters: The IPO delay follows a <a href="https://www.benzinga.com/news/24/07/39975768/bill-ackmans-us-fund-ipo-target-slashed-by-90-as-pershing-square-specifically-disclaims-ceos-comment">significant reduction in the fund&#8217;s targe</a>t, which was slashed by as much as 90% from the initial $25 billion. In a letter to investors in his Pershing Square holding company sent on Wednesday, Ackman urged, "This is a moment when you can be very helpful to Pershing Square by participating in the PSUS offering and giving your order to the banks, the sooner the better." However, Pershing Square USA "specifically disclaims" Ackman's statement in the filing that included the letter.
Inspired by Warren Buffett&#8216;s career, <a href="https://www.benzinga.com/news/24/07/39766570/bill-ackman-says-his-unofficial-mentor-warren-buffett-inspired-him-to-take-pershing-square-funds-pub">Ackman decided to take his funds public.</a> He planned to use his social media presence and a Buffett-like annual meeting to bolster his new investment fund.
Pershing Square USA is a closed-end fund set to be listed on the New York Stock Exchange, investing in large, publicly traded stocks that Ackman and his team believe are undervalued. Ackman had previously informed investors that he expected the company to trade at a premium compared to the net assets it held.
Despite the reduction in the IPO target, Ackman remains optimistic about the fund's potential, particularly with the involvement of U.S. retail investors and the&nbsp;<a href="https://www.benzinga.com/news/24/07/39811552/from-warren-buffett-style-annual-meetings-to-social-media-strategy-heres-how-bill-ackman-plans-to-bo" target="_blank" rel="noreferrer noopener">support of institutional investors</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/07/39964922/ron-desantis-says-florida-supreme-court-should-not-have-allowed-cannabis-legalization-initiative?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Ron DeSantis Says Florida Supreme Court Should &#8216;Not Have Allowed&#8217; Cannabis Legalization Initiative On Ballot</a></li>
</ul>
This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Harvard Association for Law and Business/ Tracy Tolf

IPOs

Bill Ackman's Warren Buffett-Inspired Strategy Hits A Snag? Pershing Square USA Delays IPO Indefinitely After Slashing Target By 90%

US Treasury Secretary Janet Yellen has strongly refuted allegations of manipulating the issuance of <a href="https://www.benzinga.com/topic/treasuries">Treasury securities</a>. These accusations were made by economist Nouriel Roubini who suggested that such manipulation was aimed at reducing real borrowing costs across the economy.
What Happened: Yellen dismissed Roubini&#8217;s argument that the Treasury had a strategy to ease financial conditions, in an <a href="https://www.bloomberg.com/news/articles/2024-07-26/yellen-rejects-roubini-claim-of-manipulation-in-treasuries">interview</a> with Bloomberg.
&#8220;I can assure you 100% that there is no such strategy. We have never, ever discussed anything of the sort,&#8221; Yellen said.
The paper, co-authored by Roubini and Stephen Miran, a former Treasury official under President Donald Trump, claimed that the Treasury&#8217;s actions in the fall of last year reduced 10-year Treasury yields by a quarter of a percentage point.
This is roughly equivalent to a full percentage point reduction in the Federal Reserve&#8217;s benchmark rate.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39948413/trump-era-white-house-official-anthony-scaramucci-says-kamala-harris-is-capable-and-has-a-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump-Era White House Official Anthony Scaramucci Says Kamala Harris Is Capable And Has A Great Team</a>
Joshua Frost, the Treasury&#8217;s assistant secretary for financial markets, defended the department&#8217;s actions, stating they were within market participants&#8217; expectations.
Yellen supported Frost&#8217;s statements, saying his speech provided the best explanation for the department&#8217;s approach.
Why It Matters: The allegations against Yellen come in the wake of a series of events that have put her in the spotlight.
Earlier this month, <a href="https://www.benzinga.com/government/24/07/39749545/trump-allies-slam-janet-yellen-for-manipulating-treasury-debt-auctions-to-improve-bidens-image">she was accused</a> by Republican lawmakers of manipulating Treasury debt auctions to stimulate the economy and enhance President Joe Biden‘s image. This latest development is a continuation of the scrutiny Yellen has been facing.
<a href="https://www.benzinga.com/government/24/05/38572650/janet-yellen-stands-up-for-feds-autonomy-as-trump-allies-plan-to-gain-more-control">Yellen also defended</a> the Federal Reserve&#8217;s political independence against attempts by Trump allies to undermine it.
In June, she <a href="https://www.benzinga.com/news/24/06/39348581/janet-yellen-dismisses-donald-trumps-proposal-to-replace-income-tax-with-tariffs-the-impact-would-be">publicly criticized Trump&#8217;s proposal</a> to replace parts of the U.S. income tax with increased tariffs on imported goods.
Later that month, she <a href="https://www.benzinga.com/government/24/06/39470021/janet-yellen-says-inflation-to-come-down-to-feds-2-target-by-2025-dismisses-possibility-of-us-recess">expressed confidence</a> in the American economy, dismissing the possibility of a recession and predicting that inflation would reach the Federal Reserve's 2% target by next year.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/07/39992709/kamala-harris-will-certify-2024-election-results-shes-not-going-to-burn-the-system-down-in-order?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Kamala Harris Will Certify 2024 Election Results: &#8216;She&#8217;s Not Going To Burn The System Down In Order To Save It'</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Flickr

Treasuries

Economics

Janet Yellen Rejects Economist Roubini's And Trump-Era Official's Claims Of 'Manipulation' In Treasuries: 'We Have Never, Ever Discussed Anything Of The Sort'

Alphabet Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google has severed its business ties with One Medical, a <a href="https://www.benzinga.com/topic/healthcare">primary healthcare provider</a> acquired by Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) for $3.9 billion.
What Happened: Google, previously One Medical&#8217;s largest business client, has decided to terminate its enterprise agreement with the healthcare company following Amazon&#8217;s acquisition of One Medical last year, <a href="https://www.businessinsider.com/google-drops-amazon-one-medical-2024-7">reported</a> Business Insider.
The agreement, which offered Google employees discounted or free One Medical memberships and operated One Medical care centers at some Google office locations, is set to expire at the end of 2024.
Google was an early supporter of One Medical and was its largest business customer for many years. Until 2020, One Medical disclosed that Google accounted for 10% of its net revenue.
In 2021, that dipped below 10%, and then One Medical stopped publicly sharing financials after Amazon acquired it.
See Also: <a href="https://www.benzinga.com/general/biotech/24/07/39940874/gileads-42-5k-priced-hiv-drug-could-be-made-at-just-40-annually-campaigners-urge-company-to-slash?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Gilead&#8217;s $42.5K Priced HIV Drug Could Be Made At Just $40 Annually</a>
A Google spokesperson confirmed to the publication that the existing relationship with One Medical is changing after 2024 but stressed that the decision has nothing to do with Amazon&#8217;s new ownership of the healthcare provider.
The existing One Medical centers on Google&#8217;s campus have already transitioned to Premise Health to provide more services like pharmacy, gynecology, and coordinated care on-site, the spokesperson added.
An Amazon spokesperson told Business Insider that Google employees and their dependents will continue to have One Medical memberships &#8220;sponsored&#8221; by their employer through the end of 2024.
Why It Matters: The termination of Google&#8217;s business relationship with One Medical comes amid significant changes within the healthcare provider.
In September, CEO Amir Dan Rubin <a href="https://www.benzinga.com/news/23/09/34166966/amazons-one-medical-ceo-departs-amid-significant-leadership-shift">stepped down</a> from One Medical after six years at the helm, a little over a year after Amazon&#8217;s acquisition.
This leadership shift was followed by <a href="https://www.benzinga.com/general/biotech/24/02/36971965/amazon-implements-major-job-cuts-in-one-medical-and-pharmacy-units-to-save-100m">major job cuts</a> in February, as part of a cost-saving initiative aiming to save One Medical $100 million.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/07/39954971/apple-drops-from-3rd-to-6th-in-china-amid-intensifying-competition-huawei-shipments-surge-41-in-">Apple Drops From 3rd To 6th In China Amid Intensifying Competition, Huawei Shipments Surge 41% In Q2: Report</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Amazon

AMZN

Google Cuts Ties With Amazon-Owned One Medical, But Clarifies It Is Not Due To E-Commerce Giant's $3.9B Acquisition

Following President Joe Biden&#8217;s decision to <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39885549/biden-withdraws-from-2024-race-what-that-means-for-solana-etf-prospects">withdraw from the 2024 presidential race</a>, a poll conducted by The Wall Street Journal indicates that former President Donald Trump has a slight edge over Vice President Kamala Harris.
What Happened: The poll <a href="https://www.wsj.com/politics/elections/harris-erases-trumps-lead-wsj-poll-finds-e286144d?mod=e2tw">results</a> published on Friday revealed that Trump has the support of 49% of registered voters, while Harris trails slightly behind with 47%. The WSJ poll, conducted from July 23-25, surveyed 1,000 registered voters with a margin of error&nbsp;of ±3.1 percentage points.
The latest poll also showed a significant rise in Harris&#8217;s favorability among registered voters, jumping 11 points to 46%. In comparison, Trump&#8217;s favorability was at 47% and Biden&#8217;s at 39%.
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/07/39925959/kim-jong-un-rejects-donald-trumps-friendship-claims-north-korea-says-we-do-not-care-expresses-nuclea?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Kim Jong Un Rejects Donald Trump&#8217;s Friendship Claims? North Korea Says &#8216;We Do Not Care,&#8217; Expresses Nuclear Readiness Amid Rising Tension With US</a>
In a ballot test featuring Robert F. Kennedy Jr. alongside other independent and third-party candidates, Harris secured 45% of the vote, while Trump received 44%. Kennedy garnered just 4%, and 5% of voters remained undecided. 
In the last poll, Biden trailed by six points in the multicandidate contest, the report noted.
Why It Matters: The&nbsp;<a href="https://www.benzinga.com/general/politics/24/07/39973800/trump-vs-harris-vice-president-gains-ground-lost-by-joe-biden-in-swing-states">race between Trump and Harris</a>&nbsp;is shaping up to be a close one, with Harris making up ground lost by Biden in head-to-head matchups against Trump. 
President Biden&#8217;s campaign was plagued by a lackluster debate performance and concerns about his age and mental fitness, leading to his withdrawal last week.
Since Biden&#8217;s exit, Harris has garnered several key endorsements from her party, experienced a surge in fundraising, and secured enough delegate commitments to secure the nomination.
Meanwhile, Trump has been&nbsp;<a href="https://www.benzinga.com/news/24/07/39947274/trump-takes-aim-at-kamala-harris-in-first-rally-post-bidens-exit-calls-her-a-radical-left-lunatic-vp">criticizing Harris</a>&nbsp;on immigration and inflation issues, labeling her as a &#8220;radical-left lunatic.&#8221;
There has also been speculation about whether Trump might&nbsp;<a href="https://www.benzinga.com/news/24/07/39979544/can-trump-replace-jd-vance-amid-kamala-harris-picking-pace-experts-warn-that-could-be-extraordinaril">replace his vice presidential candidate</a>, Sen. J.D. Vance, due to the latter&#8217;s underwhelming polling and Harris&#8217;s growing momentum. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39975168/nikki-haley-says-democrats-are-very-smart-to-put-in-a-younger-candidate-against-trump-but-kamala-har?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Nikki Haley Says &#8216;Democrats Are Very Smart To Put In A Younger Candidate&#8217; Against Trump But Kamala Harris Is The &#8216;Weakest Candidate&#8217;</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Via Shutterstock

Trump Vs. Harris: New Poll Shows Ex-President Leading Democratic Candidate By A Narrow Margin, But Vice President's Favorability Is Faring Better Than Biden

H&amp;R Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRB#NYSE">HRB</a>) has outperformed the market over the past 5 years by 2.77% on an annualized basis producing an average annual return of 15.37%. Currently, H&amp;R Block has a market capitalization of $7.95 billion. 
Buying $1000 In HRB: If an investor had bought $1000 of HRB stock 5 years ago, it would be worth $2,049.30 today based on a price of $56.95 for HRB at the time of writing.
<h3>H&amp;R Block's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722029438_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,000 Today

Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) has outperformed the market over the past 10 years by 5.7% on an annualized basis producing an average annual return of 16.62%. Currently, Apollo Global Management has a market capitalization of $69.51 billion. 
Buying $1000 In APO: If an investor had bought $1000 of APO stock 10 years ago, it would be worth $4,546.33 today based on a price of $122.16 for APO at the time of writing.
<h3>Apollo Global Management's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722029433_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Apollo Global Management 10 Years Ago Would Be Worth This Much Today

Citigroup analyst Atif Malik maintains Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) with a Buy and lowers the price target from $185 to $162.

Price Target

Citigroup Maintains Buy on Teradyne, Lowers Price Target to $162

During the last three months, 5 analysts shared their evaluations of Puma Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBYI#NASDAQ">PBYI</a>), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $7.0, a high estimate of $7.00, and a low estimate of $7.00. The average price target has stayed the same, reflecting a consistent view from analysts. 
<img src="https://www.benzinga.com/files/images/story/2024/1722027698_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive Puma Biotechnology is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Puma Biotechnology. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Puma Biotechnology compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Puma Biotechnology's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Puma Biotechnology's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PBYI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Puma Biotechnology analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Puma Biotechnology</h2>
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
<h3>A Deep Dive into Puma Biotechnology's Financials</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Challenges: Puma Biotechnology's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately -17.07%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Puma Biotechnology's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -11.0%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Puma Biotechnology's ROE stands out, surpassing industry averages. With an impressive ROE of -9.22%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Puma Biotechnology's ROA excels beyond industry benchmarks, reaching -2.17%. This signifies efficient management of assets and strong financial health.
Debt Management: Puma Biotechnology's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.17, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PBYI

Where Puma Biotechnology Stands With Analysts

During the last three months, 10 analysts shared their evaluations of Lennox Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>), revealing diverse outlooks from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Lennox Intl, presenting an average target of $581.9, a high estimate of $675.00, and a low estimate of $517.00. This upward trend is apparent, with the current average reflecting a 7.66% increase from the previous average price target of $540.50.
<img src="https://www.benzinga.com/files/images/story/2024/1722027675_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Lennox Intl. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$550.00</td>
<td>$517.00</td>
</tr>
<tr>
<td>Tommy Moll</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$675.00</td>
<td>$675.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$572.00</td>
<td>$566.00</td>
</tr>
<tr>
<td>Jeffrey Hammond</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$600.00</td>
<td>$515.00</td>
</tr>
<tr>
<td>Timothy Wojs</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$610.00</td>
<td>$505.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$517.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Joe Ritchie</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$575.00</td>
<td>$507.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$570.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Gautam Khanna</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$600.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$550.00</td>
<td>$520.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Lennox Intl. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Lennox Intl compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Lennox Intl's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Lennox Intl's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/LII/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Lennox Intl analyst ratings.</a>
<h2>Delving into Lennox Intl's Background</h2>
Lennox International manufactures and distributes heating, ventilating, air conditioning, and refrigeration products to replacement (75% of sales) and new construction (25% of sales) markets. In fiscal 2023, residential HVAC was 68% of sales and commercial HVAC and Heatcraft refrigeration was 32% of sales. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand. The Texas-based company is focused on North America after the sale of its European HVAC and refrigeration businesses in late 2023.
<h3>Unraveling the Financial Story of Lennox Intl</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Lennox Intl showcased positive performance, achieving a revenue growth rate of 2.81% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 16.95%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Lennox Intl's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 51.98% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Lennox Intl's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.92% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Lennox Intl's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.72, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

10 Analysts Have This To Say About Lennox Intl

Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) has outperformed the market over the past 10 years by 12.34% on an annualized basis producing an average annual return of 23.26%. Currently, Taiwan Semiconductor has a market capitalization of $837.03 billion. 
Buying $1000 In TSM: If an investor had bought $1000 of TSM stock 10 years ago, it would be worth $7,815.64 today based on a price of $161.40 for TSM at the time of writing.
<h3>Taiwan Semiconductor's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722027659_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Taiwan Semiconductor 10 Years Ago Would Be Worth This Much Today

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
We&rsquo;re diving into the biggest pre-market stock movers for Wednesday will a look at all of the latest news happening this morning.



Moving shares this morning are financial reports as we are knee-deep into the Q1 2024 earnings season.



Let&rsquo;s get into that below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Isun (NASDAQ:<a href="https://investorplace.com/stock-quotes/isun-stock-quote/">ISUN</a>) stock is rocketing more than 55% alongside heavy pre-market trading.</li>



<li>Neo-Concept International (NASDAQ:<a href="https://investorplace.com/stock-quotes/nci-stock-quote/">NCI</a>) shares are soaring over 27% without any clear news this morning.</li>



<li>Innodata (NASDAQ:<a href="https://investorplace.com/stock-quotes/inod-stock-quote/">INOD</a>) stock is surging more than 21% alongside <a href="https://finance.yahoo.com/news/innodata-reports-record-first-quarter-202000280.html">record Q1 2024 earnings</a>.</li>



<li>Repare Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/rptx-stock-quote/">RPTX</a>) shares are rising over 18% on a <a href="https://www.nasdaq.com/press-release/repare-therapeutics-provides-business-and-clinical-update-and-reports-first-quarter">clinical update and Q1 earnings</a>.</li>



<li>Helius Medical Tech (NASDAQ:<a href="https://investorplace.com/stock-quotes/hsdt-stock-quote/">HSDT</a>) stock is gaining more than 17% as it <a href="https://www.nasdaq.com/press-release/helius-medical-technologies-inc.-announces-pricing-of-%246.4-million-public-offering">bounces back from a public offering</a>.</li>



<li>Origin Agritech (NASDAQ:<a href="https://investorplace.com/stock-quotes/seed-stock-quote/">SEED</a>) shares are increasing over 16% after dropping B.F. Borgers CPA PC <a href="https://www.tipranks.com/news/company-announcements/origin-agritech-ends-ties-with-accounting-firm">as its accounting firm</a>.</li>



<li>Lucy Scientific Discovery (NASDAQ:<a href="https://investorplace.com/stock-quotes/lsdi-stock-quote/">LSDI</a>) stock is climbing more than 15% despite a lack of news today.</li>



<li>Reddit (NYSE:<a href="https://investorplace.com/stock-quotes/rddt-stock-quote/">RDDT</a>) stock is heading over 15% higher on a <a href="https://www.cnbc.com/2024/05/07/reddit-rddt-q1-2024-earnings.html">strong first earnings report</a> as a public company.</li>



<li>Louisiana-Pacific (NYSE:<a href="https://investorplace.com/stock-quotes/lpx-stock-quote/">LPX</a>) shares are jumping more than 15% after <a href="https://www.nasdaq.com/press-release/lp-building-solutions-reports-first-quarter-2024-results-and-increases-second-quarter">releasing its Q1 results</a>.</li>



<li>Clover Health Investment (NASDAQ:<a href="https://investorplace.com/stock-quotes/clov-stock-quote/">CLOV</a>) stock is up over 15% on <a href="https://finance.yahoo.com/news/clover-health-reports-strong-first-200500540.html">strong Q1 earnings</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Treace Medical Concepts (NASDAQ:<a href="https://investorplace.com/stock-quotes/tmci-stock-quote/">TMCI</a>) stock is crashing more than 56% with the release of its <a href="https://www.nasdaq.com/press-release/treace-medical-concepts-reports-first-quarter-2024-financial-results-2024-05-07">Q1 earnings report</a>.</li>



<li>DoubleVerify (NYSE:<a href="https://investorplace.com/stock-quotes/dv-stock-quote/">DV</a>) shares are plummeting over 39% after <a href="https://www.nasdaq.com/press-release/doubleverify-reports-first-quarter-2024-financial-results-2024-05-07">posting earnings for Q1 2024</a>.</li>



<li>ZoomInfo Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/zi-stock-quote/">ZI</a>) stock is diving more than 23% even after <a href="https://www.zacks.com/stock/news/2269966/zoominfo-zi-q1-earnings-and-revenues-surpass-estimates">Q1 earnings came in above estimates</a>.</li>



<li>Safe &amp; Green Development (NASDAQ:<a href="https://investorplace.com/stock-quotes/sgd-stock-quote/">SGD</a>) shares are taking an over 21% beating <a href="https://www.nasdaq.com/press-release/safe-and-green-development-corporation-to-acquire-myvonia-a-cutting-edge-ai-asset">on acquisition plans</a>.</li>



<li>Inspire Medical Systems (NYSE:<a href="https://investorplace.com/stock-quotes/insp-stock-quote/">INSP</a>) stock is tumbling more than 17% alongside its <a href="https://www.nasdaq.com/press-release/inspire-medical-systems-inc.-announces-first-quarter-2024-financial-results-and">Q1 earnings report</a>.</li>



<li>Shoals Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/shls-stock-quote/">SHLS</a>) shares are sliding over 15% after <a href="https://www.nasdaq.com/press-release/shoals-technologies-group-inc.-reports-financial-results-for-first-quarter-2024-2024">releasing Q1 results</a>.</li>



<li>Graphex (NYSEMKT:<a href="https://investorplace.com/stock-quotes/grfx-stock-quote/">GRFX</a>) stock is dropping more than 14% without any apparent news today.</li>



<li>Flywire (NASDAQ:<a href="https://investorplace.com/stock-quotes/flyw-stock-quote/">FLYW</a>) shares are slipping over 14% <a href="https://www.benzinga.com/news/24/05/38694011/flywire-reports-q1-loss-joins-zoominfo-inspire-medical-systems-and-other-big-stocks-moving-lower-in">with a Q1 loss</a>.</li>



<li>A-Mark Precious Metals (NASDAQ:<a href="https://investorplace.com/stock-quotes/amrk-stock-quote/">AMRK</a>) stock is dipping more than 13% on <a href="https://www.nasdaq.com/press-release/a-mark-precious-metals-reports-fiscal-third-quarter-2024-results-2024-05-07">fiscal Q3 earnings</a>.</li>



<li>MediaAlpha (NYSE:<a href="https://investorplace.com/stock-quotes/max-stock-quote/">MAX</a>) shares close out our pre-market stock movers down over 12% after <a href="https://www.nasdaq.com/press-release/mediaalpha-announces-pricing-of-secondary-offering-by-white-mountains-insurance-group">pricing a secondary offering</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/05/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-may-8th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

NKTR, BRFS and SEED are among premarket gainers

NKTR, BRFS and SEED are among pre-market gainers

Helius Medical Technologies GAAP EPS of -$3.08, revenue of $0.14M

Helius Medical Technologies, Inc. (HSDT) Q1 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Helius Medical Tech (NASDAQ:<a href="https://investorplace.com/stock-quotes/hsdt-stock-quote/">HSDT</a>) just reported results for the first quarter of 2024.<ul><li>Helius Medical Tech reported earnings per share of -$3.08. This was above the analyst estimate for EPS of -$3.87.</li><li>The company reported revenue of $135,000.</li><li>This was 3.85% better than the analyst estimate for revenue of $130,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/hsdt-stock-earnings-helius-medical-tech-for-q1-of-2024/">HSDT Stock Earnings: Helius Medical Tech Beats EPS, Beats Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

HSDT Stock Earnings: Helius Medical Tech Beats EPS, Beats Revenue for Q1 2024

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CARGO Therapeutics, Inc. (CRGX – Research Report), H...

Analysts Offer Insights on Healthcare Companies: CARGO Therapeutics, Inc. (CRGX), Helius Medical Technologies (HSDT) and CareCloud (CCLD)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out on Thursday morning as we dive into all of the hottest news affecting shares this morning!



Moving stocks this morning are heaving trading, earnings reports, a stock offering and more.



Let&rsquo;s get into this news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Virax Biolabs (NASDAQ:<a href="https://investorplace.com/stock-quotes/vrax-stock-quote/">VRAX</a>) stock is rocketing close to 158% alongside heavy pre-market trading.</li>



<li>Aethlon Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/aemd-stock-quote/">AEMD</a>) shares are soaring more than 94% with strong early morning trading.</li>



<li>Logistic Properties (NYSEMKT:<a href="https://investorplace.com/stock-quotes/lpa-stock-quote/">LPA</a>) stock is surging over 50% after <a href="https://www.nasdaq.com/press-release/logistic-properties-americas-ring-opening-bell-new-york-stock-exchange-2024-05-30">recently going public</a>.</li>



<li>Nauticus Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kitt-stock-quote/">KITT</a>) shares are gaining more than 27% with heavy trading this morning.</li>



<li>iSpecimen (NASDAQ:<a href="https://investorplace.com/stock-quotes/ispc-stock-quote/">ISPC</a>) stock is increasing over 25% with strong trading on Thursday morning.</li>



<li>Nanoviricides (NYSEMKT:<a href="https://investorplace.com/stock-quotes/nnvc-stock-quote/">NNVC</a>) shares are rising nearly 19% without any clear news on Thursday.</li>



<li>60 Degrees (NASDAQ:<a href="https://investorplace.com/stock-quotes/sxtp-stock-quote/">SXTP</a>) stock is heading 18% higher despite a lack of news this morning.</li>



<li>Vanda Pharmaceuticals(NASDAQ:<a href="https://investorplace.com/stock-quotes/vnda-stock-quote/">VNDA</a>) shares are climbing more than 16% as it takes part in a <a href="https://www.nasdaq.com/press-release/vanda-pharmaceuticals-announces-participation-jefferies-2024-global-healthcare">global healthcare conference starting today</a>.</li>



<li>Motorsport Games (NASDAQ:<a href="https://investorplace.com/stock-quotes/msgm-stock-quote/">MSGM</a>) stock is jumping over 15% after <a href="https://www.nasdaq.com/press-release/motorsport-games-regains-compliance-nasdaq-listing-rules-2024-06-05">regaining listing compliance</a>.</li>



<li>8&times;8 (NASDAQ:<a href="https://investorplace.com/stock-quotes/eght-stock-quote/">EGHT</a>) shares are up more than 14% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Actelis Networks (NASDAQ:<a href="https://investorplace.com/stock-quotes/asns-stock-quote/">ASNS</a>) stock is plummeting almost 45% <a href="https://investorplace.com/2024/06/why-is-actelis-networks-asns-stock-up-689-today/">after a massive rally yesterday</a>.</li>



<li>Jowell Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/jwel-stock-quote/">JWEL</a>) shares are diving over 23% after a major rally on Wednesday.</li>



<li>Sprinklr (NYSE:<a href="https://investorplace.com/stock-quotes/cxm-stock-quote/">CXM</a>) stock is tumbling more than 21% after <a href="https://www.nasdaq.com/press-release/sprinklr-announces-first-quarter-fiscal-2025-results-and-appoints-trac-pham-co-chief">cutting its revenue outlook</a>.</li>



<li>Fresh2 Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/fres-stock-quote/">FRES</a>) shares are taking a 19% beating after rallying in the prior day of trading.</li>



<li>MicroAlgo (NASDAQ:<a href="https://investorplace.com/stock-quotes/mlgo-stock-quote/">MLGO</a>) stock is sliding over 17% as it <a href="https://investorplace.com/2024/06/why-is-microalgo-mlgo-stock-up-162-today/">comes off of a recent rally</a>.</li>



<li>Helius Medical Tech (NASDAQ:<a href="https://investorplace.com/stock-quotes/hsdt-stock-quote/">HSDT</a>) shares are dropping more than 17% despite <a href="https://www.nasdaq.com/press-release/microcap-rodeos-spring-summer-conference-june-6th-2024-25-presenting-companies-2024">taking part in a conference today</a>.</li>



<li>InMed Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/inm-stock-quote/">INM</a>) stock is falling close to 17% on Thursday morning.</li>



<li>Nuvve (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvve-stock-quote/">NVVE</a>) shares are decreasing over 16% after a rally yesterday.</li>



<li>Renalytix (NASDAQ:<a href="https://investorplace.com/stock-quotes/rnlx-stock-quote/">RNLX</a>) stock is slipping more than 16% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318376664&amp;type=PDF&amp;symbol=RNLX&amp;cdn=50b6d5e78c92d2a587a022cdac0add19&amp;companyName=Renalytix+plc&amp;formType=S-3&amp;formDescription=Registration+statement+under+Securities+Act+of+1933&amp;dateFiled=2024-06-05">proposed secondary stock sale</a>.</li>



<li>Five Below (NASDAQ:<a href="https://investorplace.com/stock-quotes/five-stock-quote/">FIVE</a>) shares close out our pre-market stock movers down over 16% after <a href="https://finance.yahoo.com/news/five-below-five-q1-earnings-211505510.html">missing Q1 estimates</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-june-6th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
When does a growth stock become one of the top <a href="https://investorplace.com/stock-types/growth-stocks/">growth stocks</a> to avoid?



It sounds like the beginning of a riddle or a bad joke, but the answer is obvious &ndash; it&rsquo;s when the stock is deceptive and tricks you into believing that it can be a good buy. You look at the Portfolio Grader and get interested because a stock has a good grade specifically for growth, but then realize that it still has an &ldquo;F&rdquo; rating overall.



How can that happen?



The Portfolio Grader rates stocks based on earnings history, growth, analyst sentiment and momentum. The growth grade in particular is a popular metric for finding growth stocks to avoid.



But it&rsquo;s also important to see why a company is getting a good growth grade. Because sometimes, looking at a single factor like growth can be misleading and can&rsquo;t make up for the company&rsquo;s deficiencies in other areas.



Today, we&rsquo;re going to look at several companies that have good growth grades, and we&rsquo;ll investigate why that&rsquo;s happening in each case. But then we&rsquo;ll pull back the curtain, look at the fuller picture, and explore why these growth stocks to avoid are still getting &ldquo;F&rdquo; grades overall.



In the end, an exercise like this is a good reminder to not rely on any one metric when considering your stock portfolio. Growth is highly desirable, but the growth stocks to avoid on this list can easily drag your portfolio into the gutter.



<h2>Virgin Galactic (SPCE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/03/spce1600-300x169.jpg" alt="Virgin Galactic (SPCE) billboard on the New York Stock Exchange, across from the Fearless Girl statue. aerospace stocks"><div>Source: Tun Pichitanon / Shutterstock.com</div></div>It makes sense to jump right into one of the growth stocks to avoid that&rsquo;s been a huge disappointment &ndash; and has cost plenty of investors a lot of money along the way. 



Virgin Galactic (NYSE:<a href="https://investorplace.com/stock-quotes/spce-stock-quote/">SPCE</a>) made its name in the billionaire space race as founder Richard Branson competed with SpaceX and Blue Orgin to see which would be the first to make it into space with a civilian crew. 



You may remember that Virgin Galactic won that race, as it shot Branson into suborbital flight just a few days before Jeff Bezos did the same on a Blue Orgin rocket.



But honestly, that&rsquo;s the high point for this company. Space tourism doesn&rsquo;t feel any closer today than it did several years ago, and few people have the several hundred thousand dollars it takes to make the trip, even if the flights become a reality.



Virgin Galactic has burned through more than $1 billion in the last two years and rewarded investors with a 93% fall in stock price. SPCE recently completed a <a href="https://investorplace.com/2024/06/will-a-1-for-20-reverse-split-save-virgin-galactic-spce-stock/">1-for-20 reverse stock split</a> to push the price back over the Nasdaq threshold and maintain listing compliance, but the reality is that this is a bad stock and a weak company.



SPCE stock shows an &ldquo;A&rdquo; rating for growth in the Portfolio Grader because its revenue was up 410% in the last quarter. But sales of only $1.99 million show that people aren&rsquo;t lining up to ride a <a href="https://seekingalpha.com/article/4690417-virgin-galactic-holdings-inc-spce-q1-2024-earnings-call-transcript?source=content_type%3Areact%7Csection%3ATranscripts%7Csection_asset%3ATranscripts%7Cfirst_level_url%3Asymbol%7Cbutton%3ATitle%7Clock_status%3ANo%7Cline%3A2">Delta rocket</a> into space as early as 2026, which is the company&rsquo;s latest projections.



SPCE stock gets an &ldquo;F&rdquo; rating overall in the Portfolio Grader.



<h2>Helius Medical Technologies (HSDT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/tech1600a-300x169.jpg" alt="Image of hand touching globe with a city in the background, implying connectivity"><div>Source: Shutterstock</div></div>Helius Medical Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/hsdt-stock-quote/">HSDT</a>) is a neurotech company headquartered in eastern Pennsylvania. The company makes medical devices that help people with balance and gait issues without getting a neurological implant. It is also one of the growth stocks to avoid in the space.



The company&rsquo;s devices improve the brain&rsquo;s ability to compensate for deficiencies and rehabilitate lost brain function. For instance, its Portable Neuromodulation Stimulator stimulates the brain through nerves in the tongue. 



It&rsquo;s being used as a short-term treatment to help people with multiple sclerosis symptoms. But it&rsquo;s an expensive device, priced at more than $23,000.



The company saw <a href="https://ir.heliusmedical.com/news-releases/news-release-details/helius-medical-technologies-inc-reports-first-quarter-2024">revenue grow</a> in the first quarter, giving it a decent growth grade in the Portfolio Grader. But we&rsquo;re still not looking at a lot of money. Revenue in the first quarter was $135,000, versus $111,000 in the same quarter a year ago.



It posted a net loss of $2.5 million, the same as a year ago. The earnings per share loss of $3.08 was better than the loss of $4.22 per share from Q1 2023.



HSDT stock is down 87% this year. It has an &ldquo;A&rdquo; rating for growth but an &ldquo;F&rdquo; rating overall in the Portfolio Grader.



<h2>InMed Pharmaceuticals (INM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/aurora-cannabis-stock-1-1-300x169.jpg" alt="cannabis stocks"><div>Source: Shutterstock</div></div>InMed Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/inm-stock-quote/">INM</a>) is a Canadian company that is a clinical-stage pharmaceutical company that&rsquo;s working to develop cannabis-infused treatments for Alzheimer&rsquo;s disease, vision and skin conditions.



The company is attempting to develop an effective pipeline of drug candidates targeting CB1 and CB2 receptors. 



Its attempt to develop an anti-itch skin cream is in Phase 2 testing, and it is seeking a partnership to help it develop the product. Its other pipeline candidates for Alzheimer&rsquo;s and dry age-related macular degeneration are in preclinical trials.



Developing new therapies is an expensive undertaking and a challenge for investors because the company has to spend a lot of cash on research and development without seeing income for years, if ever.



For the third fiscal quarter of 2024 (ending March 31), InMed reported a net loss of $5.7 million. The company saw sales of $1.1 million, up slightly from a year ago, and a gross profit of $289,000, which was better than its profit of $192,511 in the same quarter a year ago.



The profit increase helps InMed&rsquo;s growth grade in the Portfolio Grader. Still, the company also acknowledges that it has money only to finance research and development into the fourth calendar quarter of 2024. That is a worrisome disclosure.



INM stock gets a &ldquo;B&rdquo; rating for growth but an &ldquo;F&rdquo; rating overall in the Portfolio Grader. The stock is down 36% this year.



<h2>P3 Health Partners (PIII)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/healthcare1600a-300x169.jpg" alt="stethoscope on a stock chart representing healthcare stocks to buy. Healthcare Stocks"><div>Source: Shutterstock</div></div>P3 Health Partners (NASDAQ:<a href="https://investorplace.com/stock-quotes/piii-stock-quote/">PIII</a>) is a health management company that supports providers with administrative services and coordination for their Medicare Advantage patients.



The company currently operates in Arizona, Oregon, Nevada, Florida and California, with a network of more than 2,900 primary care providers.



It recently announced raising <a href="https://ir.p3hp.org/news-events/press-releases/detail/106/p3-health-partners-inc-announces-approximately-42-2">$42.2 million</a> through the sale of 67.4 million units of stock with institutional investors, valued at just over 62 cents per share. That will give the company an infusion of cash to operate, but it also serves to dilute the share base.



First-quarter financial results included $388.5 million in revenue, up 29% from a year ago. But gross profits fell from $16.5 million to $6.4 million, and the company reported a net loss of $49.6 million.



PIII is among the growth stocks to avoid in part because it is down 62% this year. It gets an &ldquo;A&rdquo; rating for growth, but still has an &ldquo;F&rdquo; rating overall in the Portfolio Grader.



<h2>Sunshine Biopharma (SBFM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/biopharma-1600-300x169.jpg" alt="Illustration of a biopharma company. Doctor standing in front of various medical icons."><div>Source: Billion Photos / Shutterstock</div></div>Sunshine Biopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/sbfm-stock-quote/">SBFM</a>) is a Florida-based biopharma company developing potential treatments in oncology and antivirals.



Thanks to its ownership of a Canadian pharmacy, Nora Pharma, which distributes generic medications, Sunshine was able to show <a href="https://sunshinebiopharma.com/wp-content/uploads/20240521_SBFM-Press-Release-Reports-Q1_2024_.pdf">sales</a> of $7.5 million in the first quarter, a gain from $4.8 million a year ago. That gives it a solid grade for growth in the Portfolio Grader.



However, Sunshine is a long path to ever bringing its own drugs to market, and that&rsquo;s where the real money is made. Sunshine is currently testing a Covid-19 treatment in mice at the University of Arizona in hopes of developing a treatment for patients who cannot use Paxlovid, Molnupiravir or Remdisivir.



It has a second drug candidate, to treat cancer, ready for testing on mice as well. However, the company&rsquo;s third drug candidate, also a cancer drug, is on hold after lab tests did not yield a favorable result.



The Nora Pharma sales weren&rsquo;t enough to help Sunshine generate a profit for the quarter, either. It posted a net loss of $1.2 million versus a loss of $1.7 million in the first quarter of 2023.



SBFM stock is down 98% this year. It gets an &ldquo;A&rdquo; rating for growth but an &ldquo;F&rdquo; rating overall in the Portfolio Grader.



<h2>MicroVision (MVIS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/06/mvis1600-300x169.png" alt="Autonomous Self Driving Car Moving Through highway - Animated Scanning Visualization Concept of Artificial Intelligence Digitalizes and Analyzes Road Using Lidar. MVIS stock"><div>Source: aslysun / Shutterstock.com</div></div>With more vehicles on the road these days than ever, the advances in driver-assisted technology are pretty interesting. MicroVision (NASDAQ:<a href="https://investorplace.com/stock-quotes/mvis-stock-quote/">MVIS</a>) makes automotive lidar sensors to help driver-assistance systems and autonomous vehicles function.



The company&rsquo;s sensors are also used in industrial, smart infrastructure and robotics.



It gets a good grade for growth in the Portfolio Grader because the company increased its revenue in the first quarter, bringing in $956,000 versus $782,000 in the first quarter of 2023. That&rsquo;s a healthy percentage increase that helps give it an &ldquo;A&rdquo; grade for growth.



But then look closer. MicroVision lost <a href="https://ir.microvision.com/news/press-releases/detail/402/microvision-announces-first-quarter-2024-results">$26.3 million in the quarter</a>, versus a loss of $19 million in the same quarter a year ago. When you&rsquo;re losing that much money, an $174,000 increase in revenue doesn&rsquo;t help that much.



MVIS stock is down 59% this year. Despite its &ldquo;A&rdquo; grade for growth, MicroVision gets an &ldquo;F&rdquo; rating overall in the Portfolio Grader.



<h2>Predictive Oncology (POAI)</h2>



<a href="https://investorplace.com/wp-content/uploads/2024/02/artificial-intelligence-ai-brain-tech-1600-768x432-1.jpg"><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/artificial-intelligence-ai-brain-tech-1600-768x432-1-300x169.jpg" alt="A concept image representing AI (artificial intelligence)."></a>Predictive Oncology (NASDAQ:<a href="https://investorplace.com/stock-quotes/poai-stock-quote/">POAI</a>) is working to harness the power of artificial intelligence to help bring drugs to market. The company believes that AI can help reduce the time it takes to successfully test and manufacture a drug, and is working specifically on cancer therapies.



The company has a biobank of&nbsp;<a href="https://predictive-oncology.com/biobankai/">150,000 tumor tissue samples</a>&nbsp;and uses machine learning to help it test and discover successful molecules. It also uses AI for drug development and for clinical trials.



And it saw an uptick in revenue in the first quarter, bringing in $419,000 versus $239,000 in the first quarter of 2023.



But the company also posted a loss of $4.2 million and $1.04 per share, versus a loss of $3.4 million and 86 cents per share in the same quarter a year ago.



That&rsquo;s why POAI stock is getting an &ldquo;A&rdquo; rating for growth but an &ldquo;F&rdquo; rating overall in the Portfolio Grader. The stock is down 67% this year.



On the date of publication, neither Louis&nbsp;Navellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/market360/2024/06/7-f-rated-growth-stocks-to-avoid-right-now-june-2024/">7 F-Rated Growth Stocks to Avoid Right Now: June 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 F-Rated Growth Stocks to Avoid Right Now: June 2024

Helius Medical Technologies (HSDT) has provided an update. Helius Medical Technologies, Inc. has successfully amended its 2022 Equity Incentive Pla...

Helius Medical Technologies Enhances Equity Plan and Confirms Directors

AEMD

AMRK

ASNS

CCLD

CLOV

CRGX

EGHT

FIVE

FLYW

FRES

GRFX

HSDTW

INOD

INSP

ISPC

ISUN

JWEL

KITT

LSDI

MLGO

MVIS

NNVC

NVVE

PIII

POAI

RDDT

RNLX

RPTX

SBFM

SEED

SHLS

SPCE

SXTP

TMCI

VNDA

VRAX

Press Releases

Helius Medical Technologies, Inc. Announces Preliminary CMS Payment Determination of Reimbursement for Portable Neuromodulation Stimulator (PoNS®)

Helius Medical Technologies, Inc. Announces Pricing of $6.4 Million Public Offering

Helius Medical Technologies, Inc. to Release First Quarter 2024 Financial Results on May 13, 2024

Earnings

Helius Medical Technologies, Inc. Reports First Quarter 2024 Financial Results

Helius Medical Technologies, Inc. Announces PoNS® Is Now Available on the Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage Contracts

Helius Medical Technologies to Exhibit at 2024 CMSC Annual Meeting, Marking a Year of Achievements: Making PoNS More Available to People with MS

Helius Medical Technologies, Inc. Announces Third-Party Reimbursement for PoNS® from Major Insurance Carrier

Biotech

Events

Helius Medical Technologies, Inc. to Present at the Spring MicroCap Rodeo Conference

MicroCap Rodeo's Spring into Summer Conference, June 6th 2024 - 25 Presenting Companies

Helius Medical Technologies, Inc. Completes Site Participation Enrollment for its U.S. Registrational Program in Stroke

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

Helius Medical Tech

Helius Medical Tech (HSDT) Forecast

Helius Medical Tech (NASDAQ:HSDT) Stock, Quote.Headers.trade-ideas